Dr. Adam R. Metwalli joins Chesapeake Urology Associates, expanding urologic oncology treatment services
Published On: 10/29/2008
BALTIMORE - Dr. Sanford J. Siegel, President and CEO of Chesapeake Urology Associates (CUA), announces the addition of Dr. Adam R. Metwalli. Dr. Metwalli will practice in CUA's Columbia, MD office. As the nation's second largest urology practice, CUA offers broad urology services, including identification and treatment of a range of urologic cancers, laparoscopy and robotics surgery, which will expand with Dr. Metwalli's expertise.
Fellowship trained in urologic oncology at the University of Texas MD Anderson Cancer Center, Dr. Metwalli recently finished a clinical fellowship with the Urologic Oncology Branch of the prestigious National Cancer Institute, National Institutes of Health. Dr. Metwalli specializes robotics surgery and in urologic cancers, including kidney tumors, prostate cancer, bladder cancer, cancer of the penis, urethral cancer and complex cancer cases. Dr. Metwalli will also treat patients for general urology needs.
Dr. Metwalli received undergraduate cum laude honors from Wake Forest University and graduate honors from Wake Forest University School of Medicine. He completed his residency at Oklahoma University Health Science Center. Dr. Metwalli received a number of awards during his training, including the Pfizer Scholar in Urology in 2003 and the Best of ASCO Travel Scholarship in 2007. Dr. Metwalli is an active member of the American Urological Association and the Endourological Society. He has been published in numerous urologic journals and recently authored a chapter in "Clinical Oncology, 3rd Edition."
As one of the East Coast's premier urology private medical practices, Chesapeake Urology Associates, P.A. (CUA) provides superior care often limited to university programs. More than 300 staff members, including a team of fellowship-trained urologists, provide men, women and children with the highest quality, comprehensive urologic care in an environment of compassion and dignity. CUA offers the most advanced minimally-invasive laparoscopic and robotics procedures and leading-edge diagnostic techniques at 20 offices in the Baltimore Metropolitan Area.
In addition, CUA operates specialty centers focusing on incontinence, infertility and male reproductive medicine, as well as the Chesapeake Urology Research Associates (CURA), which conducts state-of-the-art drug studies for erectile dysfunction, bladder and prostate disease and cancer, to provide patients and the community with leading care for all urological conditions including urinary incontinence, prostate screening, prostate cancer, erectile dysfunction, vasectomies and fertility. CUA's unique Center for Integrative Medicine also provides nutrition, physical therapy, acupuncture and sexual therapy services. For more information, visit www.chesapeakeurology.com.